{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:21:05Z","timestamp":1765884065689,"version":"3.48.0"},"reference-count":34,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2023B1515120028"],"award-info":[{"award-number":["2023B1515120028"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guangdong Provincial People\u2019s Hospital for NSFC","award":["8217040449"],"award-info":[{"award-number":["8217040449"]}]},{"name":"Guangdong Provincial People\u2019s Hospital for NSFC","award":["8217040546"],"award-info":[{"award-number":["8217040546"]}]},{"name":"Guangdong Provincial People\u2019s Hospital for NSFC","award":["8220040257"],"award-info":[{"award-number":["8220040257"]}]},{"name":"Guangdong Provincial People\u2019s Hospital for NSFC","award":["8227040339"],"award-info":[{"award-number":["8227040339"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171075"],"award-info":[{"award-number":["82171075"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271125"],"award-info":[{"award-number":["82271125"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82301205"],"award-info":[{"award-number":["82301205"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82301260"],"award-info":[{"award-number":["82301260"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U24A20707"],"award-info":[{"award-number":["U24A20707"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients with Persistent Diabetic Macular Edema","award":["2024-29"],"award-info":[{"award-number":["2024-29"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024T170185"],"award-info":[{"award-number":["2024T170185"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Scientific Research Foundation of Guangdong Province","award":["A2021378"],"award-info":[{"award-number":["A2021378"]}]},{"name":"Science and Technology Program of Guangzhou, China","award":["20220610092"],"award-info":[{"award-number":["20220610092"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Persistent diabetic macular edema (DME) with inadequate responsiveness to conventional inhibitors of vascular endothelial growth factor (VEGF) has caused significant vision loss and substantial treatment burdens. Brolucizumab is a new-generation anti-VEGF agent with better anatomical efficacy and prolonged duration of action. This single-centre, open-label, single-arm design clinical trial aims to evaluate the efficacy and safety of intravitreal brolucizumab 6\u2009mg in Chinese subjects with persistent DME.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A total of 52 adult subjects with persistent DME will be recruited from Guangdong Provincial People\u2019s Hospital. All study eyes will receive three consecutive 6\u2009mg brolucizumab injections at intervals of 6 weeks. Disease activity assessment (DAA) will be arranged at week 18, and if disease activity is detected, subjects will continue with dosing of brolucizumab every 6 weeks (at weeks 18 and 24). Otherwise, the dosing will be adjusted to every 12 weeks (at week 24). The primary endpoints will be the proportion of patients with central subfield thickness (CST) &lt;300\u2009\u00b5m and the proportion of patients with \u22655 letters visual improvement at week 28. The secondary endpoints will involve anatomical changes assessed through multimodal imaging techniques containing optical coherence tomography (OCT), OCT angiography (OCTA), ultrawide-field fundus photograph (UWFP), ultrawide-field fluorescein angiography (UWFFA), as well as safety assessment. Additionally, aqueous samples will be collected and cytokine levels will be assessed for exploratory analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study has been approved by the Ethics Review Committee of Guangdong Provincial People\u2019s Hospital (KY2024-319). This study will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the ICH E6 guidelines for Good Clinical Practice and the applicable regulatory requirements. The study results will be submitted to a peer-reviewed journal and presented at both local and international congresses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06498050\">NCT06498050<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-099551","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T10:35:35Z","timestamp":1753698935000},"page":"e099551","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Brolucizumab efficacy and safety single-arm descriptive trial in patients with persistent diabetic macular edema (BEST study): protocol for a single-centre, open-label, single-arm clinical trial in China"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06498050","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06498050","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06498050","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04058067","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04058067","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ziyi","family":"Huang","sequence":"first","affiliation":[{"name":"Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China"},{"name":"Shantou University Medical College, Shantou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunyan","family":"Hu","sequence":"additional","affiliation":[{"name":"Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxiao","family":"Shen","sequence":"additional","affiliation":[{"name":"Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anyi","family":"Liang","sequence":"additional","affiliation":[{"name":"Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Fang","sequence":"additional","affiliation":[{"name":"Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Zeng","sequence":"additional","affiliation":[{"name":"Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyi","family":"Liao","sequence":"additional","affiliation":[{"name":"Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2574-0446","authenticated-orcid":false,"given":"Chunwen","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyi","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Hu","sequence":"additional","affiliation":[{"name":"Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-823X","authenticated-orcid":false,"given":"Dan","family":"Cao","sequence":"additional","affiliation":[{"name":"Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3308-4633","authenticated-orcid":false,"given":"Honghua","family":"Yu","sequence":"additional","affiliation":[{"name":"Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China"},{"name":"Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"2025121603192130000_15.7.e099551.1","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.survophthal.2022.01.009","article-title":"Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: A systematic review and meta-analysis","volume":"67","author":"Im","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"2025121603192130000_15.7.e099551.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414264"},{"key":"2025121603192130000_15.7.e099551.3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000502779","article-title":"The Diabetic Retinopathy Clinical Research Network (DRCR.net) and Its Contributions to the Treatment of Diabetic Retinopathy","volume":"62","author":"Sun","year":"2019","journal-title":"Ophthalmic Res"},{"key":"2025121603192130000_15.7.e099551.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2022.11.008"},{"key":"2025121603192130000_15.7.e099551.5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","article-title":"Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial","volume":"136","author":"Bressler","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"2025121603192130000_15.7.e099551.6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/eye.2017.111","article-title":"Identification of time point to best define \u2018sub-optimal response\u2019 following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data","volume":"31","author":"Chatziralli","year":"2017","journal-title":"Eye (Lond)"},{"key":"2025121603192130000_15.7.e099551.7","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00417-017-3624-y","article-title":"Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema","volume":"255","author":"Bahrami","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2025121603192130000_15.7.e099551.8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/IAE.0000000000002253","article-title":"Aflibercept for persistent diabetic macular Edema: Forty-Eight-Week Outcomes","volume":"39","author":"Bahrami","year":"2019","journal-title":"Retina (Philadelphia)"},{"key":"2025121603192130000_15.7.e099551.9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoc.2021.101197","article-title":"Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series","volume":"24","author":"Chakraborty","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2025121603192130000_15.7.e099551.10","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13061819","article-title":"Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Na\u00efve and Therapy-Refractory Patients with Diabetic Macular Edema","volume":"13","author":"R\u00fcbsam","year":"2024","journal-title":"J Clin Med"},{"key":"2025121603192130000_15.7.e099551.11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/ICU.0000000000000849","article-title":"Brolucizumab for the treatment of diabetic macular edema","volume":"33","author":"Kuo","year":"2022","journal-title":"Curr Opin Ophthalmol"},{"key":"2025121603192130000_15.7.e099551.12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.oret.2017.07.004","article-title":"A Prospective Randomized Comparative Dosing Trial of Ranibizumab In Bevacizumab-Resistant Diabetic Macular Edema: The REACT Study","volume":"2","author":"Ehlers","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"2025121603192130000_15.7.e099551.13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3928\/23258160-20161031-07","article-title":"Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial","volume":"47","author":"Fechter","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2025121603192130000_15.7.e099551.14","doi-asserted-by":"crossref","first-page":"735318","DOI":"10.3389\/fmed.2021.735318","article-title":"Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up","volume":"8","author":"Lu","year":"2021","journal-title":"Front Med"},{"key":"2025121603192130000_15.7.e099551.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.08.026"},{"key":"2025121603192130000_15.7.e099551.16","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.survophthal.2016.03.010","article-title":"Vascular endothelial growth factor and diabetic macular edema","volume":"61","author":"Lally","year":"2016","journal-title":"Surv Ophthalmol"},{"key":"2025121603192130000_15.7.e099551.17","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1111\/aos.14514","article-title":"Prediction of response to anti-vascular endothelial growth factor treatment in diabetic macular oedema using an optical coherence tomography-based machine learning method","volume":"99","author":"Cao","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"2025121603192130000_15.7.e099551.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-017-3647-4"},{"key":"2025121603192130000_15.7.e099551.19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/2474126420953067","article-title":"Evaluation of Patients Receiving Intravitreal Antivascular Endothelial Growth Factor for Diabetic Macular Edema in Clinical Practice in the United States","volume":"5","author":"Pitcher","year":"2021","journal-title":"J Vitreoretin Dis"},{"key":"2025121603192130000_15.7.e099551.20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000513048","article-title":"Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration","volume":"244","author":"Tadayoni","year":"2021","journal-title":"Ophthalmologica"},{"key":"2025121603192130000_15.7.e099551.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.12.031"},{"key":"2025121603192130000_15.7.e099551.22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2023.07.012","article-title":"KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema","volume":"260","author":"Wykoff","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"2025121603192130000_15.7.e099551.23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41433-021-01816-3","article-title":"Brolucizumab\u2014early experience with early extended interval regime in chronic centre involved diabetic macular oedema","volume":"36","author":"Chakraborty","year":"2022","journal-title":"Eye (Lond)"},{"key":"2025121603192130000_15.7.e099551.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"2025121603192130000_15.7.e099551.25","unstructured":"Novartis Pharmaceuticals . To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema (KINGLET). ClinicalTrials.gov. NCT04058067. Primary completion: 2023 Jan 31. Results first posted: 2024 Sep 19. Results last posted: 2024 Oct 9, Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04058067"},{"key":"2025121603192130000_15.7.e099551.26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.4914"},{"key":"2025121603192130000_15.7.e099551.27","first-page":"639","article-title":"Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema","volume":"12","author":"Garweg","year":"2023","journal-title":"Ophthalmol Diabetol Treat Aspects Ophthalmol Ther"},{"key":"2025121603192130000_15.7.e099551.28","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.2147\/OPTH.S339393","article-title":"Brolucizumab: Evaluation of Compassionate Use of a Complex Anti-VEGF Therapy","volume":"15","author":"Murray","year":"2021","journal-title":"OPTH"},{"key":"2025121603192130000_15.7.e099551.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-37726-5","article-title":"Evaluating initial responses to brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: a retrospective, single-center, observational study","volume":"13","author":"Hirano","year":"2023","journal-title":"Sci Rep"},{"key":"2025121603192130000_15.7.e099551.30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"2025121603192130000_15.7.e099551.31","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamaophthalmol.2023.5248","article-title":"Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial","volume":"141","author":"Singh","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"2025121603192130000_15.7.e099551.32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/08820538.2023.2271095","article-title":"Safety and Efficacy of Brolucizumab in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy: A Systematic Review and Meta-Analysis","volume":"39","author":"Abu Serhan","year":"2024","journal-title":"Semin Ophthalmol"},{"key":"2025121603192130000_15.7.e099551.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.06.028"},{"key":"2025121603192130000_15.7.e099551.34","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s13300-023-01410-8","article-title":"Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis","volume":"14","author":"Sydnor","year":"2023","journal-title":"Diabetes Ther"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-099551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:19:33Z","timestamp":1765883973000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-099551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,28]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjopen-2025-099551"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-099551","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}